Managing blood vessel development by preventing its growth from tumors in cancer patients or stimulating its development in cardiac disease patients is apparently an idea whose time has come. William Li, president and medical director of the non-profit Angiogenesis Foundation in Boston, notes that using such control as a way to fight disease interpenetrates highly varied fields of medicine. "Angiogenesis is a common denominator in many of society's most significant medical conditions," says Li. He adds that when knowledge is integrated effectively, this single approach of angiogenesis research can contribute to conquering these conditions and can actually create an entire new field of medicine based on angiogenesis.

It's an idea that the pharmaceutical industry has embraced. According to a recent Business Communications Company report1; angiogenesis drugs are expected to be a $2.4 billion market by 2006. The report estimates that 300 angiogenesis inhibitors for cancer treatment strategies...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?